GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (LTS:0Q1G) » Definitions » Cyclically Adjusted Revenue per Share

Eli Lilly and Co (LTS:0Q1G) Cyclically Adjusted Revenue per Share : CHF18.25 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share for the three months ended in Jun. 2024 was CHF11.173. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF18.25 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Eli Lilly and Co was 9.50% per year. The lowest was 1.80% per year. And the median was 7.10% per year.

As of today (2024-09-21), Eli Lilly and Co's current stock price is CHF540.00. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was CHF18.25. Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is 29.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.10. And the median was 5.48.


Eli Lilly and Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Revenue per Share Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.63 20.01 20.22 18.05 26.74

Eli Lilly and Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.64 13.06 26.74 20.67 18.25

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=11.173/132.5538*132.5538
=11.173

Current CPI (Jun. 2024) = 132.5538.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 4.252 100.428 5.612
201412 4.668 99.070 6.246
201503 4.265 99.621 5.675
201506 4.355 100.684 5.734
201509 4.528 100.392 5.979
201512 5.023 99.792 6.672
201603 4.490 100.470 5.924
201606 4.943 101.688 6.443
201609 4.763 101.861 6.198
201612 5.519 101.863 7.182
201703 4.957 102.862 6.388
201706 5.334 103.349 6.841
201709 5.157 104.136 6.564
201712 3.086 104.011 3.933
201803 4.482 105.290 5.643
201806 5.367 106.317 6.691
201809 5.007 106.507 6.232
201812 5.475 105.998 6.847
201903 5.178 107.251 6.400
201906 6.023 108.070 7.388
201909 5.906 108.329 7.227
201912 6.562 108.420 8.023
202003 6.166 108.902 7.505
202006 5.743 108.767 6.999
202009 5.763 109.815 6.956
202012 7.229 109.897 8.719
202103 6.935 111.754 8.226
202106 6.721 114.631 7.772
202109 6.862 115.734 7.859
202112 7.959 117.630 8.969
202203 8.008 121.301 8.751
202206 6.972 125.017 7.392
202209 7.475 125.227 7.912
202212 7.517 125.222 7.957
202303 7.131 127.348 7.423
202306 8.291 128.729 8.537
202309 9.496 129.860 9.693
202312 8.949 129.419 9.166
202403 8.621 131.776 8.672
202406 11.173 132.554 11.173

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Eli Lilly and Co  (LTS:0Q1G) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=540.00/18.25
=29.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.10. And the median was 5.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Eli Lilly and Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co Headlines

No Headlines